Original Literature | Model OverView |
---|---|
Publication
Title
TGF-beta signaling from receptors to the nucleus.
Affiliation
Laboratory of Cell Regulation and Carcinogenesis, National Cancer InstituteBuilding 41, Room C629, 41 Library Drive, MSC 5055, Bethesda, MD 20892-5055,USA.
Abstract
In the past three years, a novel signal transduction pathway downstream of thetransforming growth factor-beta (TGF-beta) superfamily receptor serine-threoninekinases has been shown to be mediated by a family of latent transcriptionfactors called 'Smads'. These proteins mediate a short-circuited pathway inwhich a set of receptor-activated Smads are phosphorylated directly by thereceptor kinase and then translocate to the nucleus complexed to the commonmediator, Smad4, to participate in transcriptional complexes. Smads 2 and 3mediate signals predominantly from the TGF-beta receptors. Of these, specificroles have been ascribed to Smad3 in control of chemotaxis of neutrophils andmacrophages and the inhibition of Smad3 activity by the oncogene Evi-1 suggeststhat it may play a role in leukemogenesis. Other data, such as the induction bythe inflammatory cytokine interferon-gamma of an inhibitory Smad, Smad7, whichblocks the actions of Smad3, suggest that identification of the specific genetargets of Smad proteins in immune cells will provide new insight into themechanisms of TGF-beta action on these cells.
PMID
10611754
|
Entity
MAPKs
--
MO000000077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m86
10
infinite
0
TRANSPATH | MO000000077 |
--
endoglin
--
MO000004387
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m501
10
infinite
0
InterPro | IPR001507 |
TRANSPATH | MO000004387 |
--
Smad4: Smad4
--
MO000017458
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2280
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000017458 |
--
Smad2
--
MO000017658
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2422
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000017658 |
--
TGFbetaR-III (2)
--
MO000017733
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2490
10
infinite
0
InterPro | IPR001507 |
TRANSPATH | MO000017733 |
--
Smad1
--
MO000017762
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2519
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000017762 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
TGFbeta: TBR2 (2)
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
TGFbeta: TBR2 (2): ALK-1(2)
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m12
0
infinite
0
--
TGFbeta: TBR2 (2): ALK-5(2)
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m13
0
infinite
0
--
TGFbeta3: TBR2 (2): TGFbetaR-III (2)
--
e14
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m14
0
infinite
0
--
TGFbeta1: TBR2 (2)
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m15
0
infinite
0
--
TGFbeta2: TBR2 (2)
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m16
0
infinite
0
--
TGFbeta3: TBR2 (2)
--
e17
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
TGFbeta2: TBR2 (2): TGFbetaR-III (2)
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m18
0
infinite
0
--
TGFbeta1: TBR2 (2): TGFbetaR-III (2)
--
e19
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m19
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TGFbeta1: TBR2 (2): endoglin
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m20
0
infinite
0
--
TGFbeta3: TBR2 (2): endoglin
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m21
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m22
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m23
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD {p}
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m24
0
infinite
0
--
SMAD {p}
--
e25
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m25
0
infinite
0
--
SMAD {p}: Smad4: Smad4
--
e26
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m26
0
infinite
0
--
SMAD {p}: Smad4: Smad4 {nucleus}
--
e27
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m27
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: phosphosphotidyl inositol-3-phosphate: SARA: SMAD2
--
e28
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m28
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: phosphosphotidyl inositol-3-phosphate: SARA: SMAD2 {p}
--
e29
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
SMAD2 {p}: Smad4: Smad4
--
e30
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m30
0
infinite
0
--
SMAD2 {p}
--
e31
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m31
0
infinite
0
--
SMAD2 {p}: Smad4: Smad4 (nucleus)
--
e32
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m32
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD3
--
e33
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m33
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD3 {p}
--
e34
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m34
0
infinite
0
--
SMAD3 {p}
--
e35
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m35
0
infinite
0
--
SMAD3 {p}: Smad4: Smad4
--
e36
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m36
0
infinite
0
--
SMAD3 {p}: Smad4: Smad4(nucleus)
--
e37
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m37
0
infinite
0
--
activin: Type II receptor (2): Type I activin recptor (2) {p}: SMAD2
--
e38
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m38
0
infinite
0
--
activin: Type II receptor (2): Type I activin recptor (2) {p}: SMAD3
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m39
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD1
--
e40
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m40
0
infinite
0
--
Type II receptor (2)
--
e41
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m41
0
infinite
0
--
activin: Type II receptor (2)
--
e42
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m42
0
infinite
0
--
Type I activin recptor (2)
--
e43
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m43
0
infinite
0
--
activin: Type II receptor (2): Type I activin recptor (2)
--
e44
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m44
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: SMAD1 {p}
--
e45
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m45
0
infinite
0
--
SMAD1 {p}
--
e46
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m46
0
infinite
0
--
BMP2: Type II receptor (2)
--
e47
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m47
0
infinite
0
--
Type I receptor (2)
--
e48
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m48
0
infinite
0
--
BMP2: Type II receptor (2): Type I receptor (2)
--
e49
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m49
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2)
--
e5
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
csml-variable:Double
m6
10
infinite
0
Affymetrix | 231776_at |
Ensembl | ENSG00000163508 |
HGNC | EOMES |
InterPro | IPR008967 |
OMIM | 604615 |
Proteome | HumanPSD/EOMES |
RefSeq | NM_005442 |
TRANSFAC | T04395 |
TRANSPATH | MO000028249 |
Unigene | Hs.147279 |
UniProt | O95936 |
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
BMP2: Type II receptor (2): Type I receptor (2) {p} : SMAD1
--
e63
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m63
0
infinite
0
--
BMP2: Type II receptor (2): Type I receptor (2) {p}
--
e64
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m64
0
infinite
0
--
activin: Type II receptor (2): Type I activin recptor (2) {p}
--
e65
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m65
0
infinite
0
--
BMP2: Type II receptor (2): Type I receptor (2) {p} : SMAD1 {p}
--
e66
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m66
0
infinite
0
--
SMAD1 {p}: Smad4: Smad4
--
e67
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m67
0
infinite
0
--
SMAD1 {p}: Smad4: Smad4 (nucleus)
--
e68
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m68
0
infinite
0
--
Smad4
--
e69
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m69
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
phosphosphotidyl inositol-3-phosphate
--
e70
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m70
0
infinite
0
--
phosphosphotidyl inositol-3-phosphate: SARA
--
e71
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m71
0
infinite
0
--
TGFbeta: TBR2 (2): Tbr-1(2) {p}: phosphosphotidyl inositol-3-phosphate: SARA
--
e72
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m72
0
infinite
0
--
SMAD2 {p}: Smad4: Smad4 (nuclus): FAST1
--
e73
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m73
0
infinite
0
--
csml-variable:Double
m74
10
infinite
0
Affymetrix | 131293_at |
Ensembl | ENSMUSG00000033837 |
MGD | Foxh1 |
Proteome | HumanPSD/Foxh1 |
RefSeq | NM_007989 |
TRANSFAC | T04100 |
TRANSPATH | MO000028003 |
Unigene | Mm.42011 |
UniProt | Q9R241 |
--
SMAD3 {p}: Smad4: Smad4(nucleus): c-Jun
--
e75
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m76
0
infinite
0
--
SMAD3 {p}: Smad4: Smad4(nucleus): c-Fos
--
e76
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m77
0
infinite
0
--
CBP:p300
--
e77
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m78
10
infinite
0
TRANSPATH | MO000103331 |
--
CBP: p300: SMAD1 {p}: Smad4: Smad4 (nucleus)
--
e78
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m79
0
infinite
0
--
CBP: p300: SMAD3 {p}: Smad4: Smad4(nucleus)
--
e79
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m80
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
CBP: p300: SMAD2 {p}: Smad4: Smad4 (nucleus)
--
e80
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m81
0
infinite
0
--
CBP: p300: SMAD {p}: Smad4: Smad4 {nucleus}
--
e81
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m82
0
infinite
0
--
CBP: p300: E1A
--
e82
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m83
0
infinite
0
--
EGF: EGFR
--
e83
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m85
0
infinite
0
--
IFN gamma: IFNgamma receptor
--
e84
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m87
0
infinite
0
--
IFNgamma receptor
--
e85
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m90
0
infinite
0
--
HGF receptor
--
e86
cso30:c:Protein
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m88
0
infinite
0
--
HGF: HGF receptor
--
e87
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m89
0
infinite
0
--
MSG1
--
e88
cso30:c:Protein
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m91
0
infinite
0
--
SMAD {p}: Smad4: Smad4 {nucleus}: MSG1
--
e89
cso30:c:Complex
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m92
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c5 : 1
m1746*m6*0.1
nodelay
--
0
PMID: 10611754, 9759503, 9393997, 9561843 Receptor complexes are heterotetrameric, consisting of two ¡Ætype II' receptors (75?85 kDa), which bind ligand, and two signal transducing ¡Ætype I' receptors (50?60 kDa) which, in most instances, cannot bind ligand directly and thus are considered to act downstream of the type II receptor. PMID: 10611754 Signals from all three isoforms of TGF-beta appear to be mediated by a single type II receptor called TBR-II and one type I receptor referred to either as TBR-I or ALK-5 (activin receptor-like kinase).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c30 : 1
stoichiometry:c28 : 1
m15*m2490*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c35 : 1
m15*m501*0.1
nodelay
--
0
PMID: 10611754 Unlike betaglycan, endoglin binds TGF-beta1 and TGF-beta3 selectively.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c34 : 1
stoichiometry:c36 : 1
m17*m501*0.1
nodelay
--
0
PMID: 10611754 Unlike betaglycan, endoglin binds TGF-beta1 and TGF-beta3 selectively.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
m5*0.1
nodelay
--
0
PMID: 10611754 This model for receptor activation involves potentiation of the kinase activity of the type I receptor by phosphorylation of several residues in a glycine-serine-rich juxtamembrane domain (GS domain) by the type II receptor kinase.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c39 : 1
stoichiometry:c40 : 1
stoichiometry:c41 : 1
m23*m1761*0.1
nodelay
--
0
PMID: 10611754 receptor-activated Smads bind to and are phosphorylated on two C-terminal serine residues in their MH2 domain by the type I receptor kinase.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c42 : 1
stoichiometry:c43 : 1
m22*0.1
nodelay
--
0
PMID: 10611754 receptor-activated Smads bind to and are phosphorylated on two C-terminal serine residues in their MH2 domain by the type I receptor kinase.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c47 : 1
stoichiometry:c49 : 1
m25*m2280*0.1
nodelay
--
0
PMID: 10611754 the phosphorylated, pathway-specific Smads then hetero-oligomerize in the cytoplasm with the common mediator, Smad4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c48 : 1
stoichiometry:c45 : 1
m24*0.1
nodelay
--
0
PMID: 10611754 the phosphorylated, pathway-specific Smads then hetero-oligomerize in the cytoplasm with the common mediator, Smad4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m26*0.1
nodelay
--
0
PMID: 10611754 the heteromeric Smad4-containing complex is then translocated to the nucleus where it mediates transcriptional activation of the target gene.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c52 : 1
stoichiometry:c125 : 1
stoichiometry:c54 : 1
m2422*m23*m71*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors. PMID: 10611754 The FYVE domain of SARA is predicted to interact with phosphosphotidyl inositol-3-phosphate in the cell membrane while an adjacent Smad binding domain recruits Smad2/3 from the cytoplasmic reservoir; the C-terminal domain anchors the Smad-SARA complex to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c3 : 1
stoichiometry:c6 : 1
stoichiometry:c4 : 1
m11*m87297*0.1
nodelay
--
0
PMID: 10611754 The assembly of the heteromeric complex is initiated by ligand binding and stabilized by interactions between the cytoplasmic domains of the type II and type I receptors. PMID: 10611754 Signals from all three isoforms of TGF-beta appear to be mediated by a single type II receptor called TBR-II and one type I receptor referred to either as TBR-I or ALK-5 (activin receptor-like kinase).
p20
p20
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c56 : 1
stoichiometry:c126 : 1
stoichiometry:c67 : 1
m23*m2276*m71*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors. PMID: 10611754 The FYVE domain of SARA is predicted to interact with phosphosphotidyl inositol-3-phosphate in the cell membrane while an adjacent Smad binding domain recruits Smad2/3 from the cytoplasmic reservoir; the C-terminal domain anchors the Smad-SARA complex to the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m28*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c59 : 1
stoichiometry:c61 : 1
stoichiometry:c127 : 1
m29*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c63 : 1
stoichiometry:c64 : 1
m2280*m31*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c178 : 1
stoichiometry:c66 : 1
m30*m89*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors. PMID: 10611754 Examples are the activating phosphorylation and nuclear translocation of Smad2 following treatment of cells with HGF [54] or activation of the SAPK/JNK pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c72 : 1
stoichiometry:c69 : 1
m34*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c70 : 1
m33*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c74 : 1
stoichiometry:c75 : 1
m35*m2280*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
m36*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c109 : 1
stoichiometry:c89 : 1
m2276*m65*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c8 : 1
stoichiometry:c7 : 1
stoichiometry:c9 : 1
m2477*m11*0.1
nodelay
--
0
PMID: 10611754, 10187774 Another type I receptor, ALK-1, expressed on endothelial cells and mutated in the autosomal dominant disorder hereditary hemorrhagic telangiectasia (HHT), can also complex with ligand-bound TBR-II, but its role in signaling is presently not understood.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c86 : 1
stoichiometry:c108 : 1
stoichiometry:c88 : 1
m2422*m65*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c78 : 1
stoichiometry:c79 : 1
stoichiometry:c80 : 1
m23*m2519*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c81 : 1
stoichiometry:c82 : 1
stoichiometry:c83 : 1
m1747*m41*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c85 : 1
stoichiometry:c90 : 1
m42*m43*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c94 : 1
m40*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c96 : 1
stoichiometry:c113 : 1
m45*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m41*m2486*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c101 : 1
stoichiometry:c102 : 1
m47*m48*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
stoichiometry:c107 : 1
m2519*m64*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c105 : 1
stoichiometry:c106 : 1
m49*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c11 : 1
stoichiometry:c10 : 1
stoichiometry:c12 : 1
m2271*m11*0.1
nodelay
--
0
PMID: 10611754 Signals from all three isoforms of TGF-beta appear to be mediated by a single type II receptor called TBR-II and one type I receptor referred to either as TBR-I or ALK-5 (activin receptor-like kinase).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c92 : 1
m44*0.1
nodelay
--
0
PMID: 10611754, 9311995, 8752209 Of the five receptor-activated Smads identified thus far, Smad2 and 3 have been shown to mediate signals from TGF-beta and activin receptors.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c111 : 1
m66*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c110 : 1
stoichiometry:c112 : 1
m63*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c115 : 1
stoichiometry:c116 : 1
stoichiometry:c117 : 1
m2280*m46*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c118 : 1
stoichiometry:c171 : 1
stoichiometry:c174 : 1
stoichiometry:c119 : 1
m67*0.1
nodelay
--
0
PMID: 10611754, 9788633 Smad1 is phosphorylated and partners with Smad4 following treatment of human breast cancer cells with either BMP-2 or TGF-beta. PMID: 10611754 Treatment of cells with EGF or hepatocyte growth factor (HGF) results in phosphorylation of Smad1 on these sites by the Erk subfamily of MAP kinases, and in retention of the linker-region phosphorylated Smad1 in the cytoplasm, blocking the nuclear translocation and transcriptional activating activity of Smad1/Smad4 complexes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c120 : 1
stoichiometry:c121 : 1
m69*0.1
nodelay
--
0
PMID: 10611754, 9214508, 9670020 Determination of the tertiary structure of the C-terminal domain of Smad4 shows that it associates as a homotrimer [25], and data now suggest that hetero-oligomeric Smads are also trimeric.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c122 : 1
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m2423*m70*0.1
nodelay
--
0
PMID: 19611754 he FYVE domain of SARA is predicted to interact with phosphosphotidyl inositol-3-phosphate in the cell membrane while an adjacent Smad binding domain recruits Smad2/3 from the cytoplasmic reservoir.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c128 : 1
stoichiometry:c130 : 1
m23*0.1
nodelay
--
0
PMID: 10611754 The mRNAs for Smad6 and Smad7 are rapidly induced by treatment of cells with TGF-beta suggesting that anti-Smads are direct effectors of a ligand-induced signal to suppress a response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c129 : 1
stoichiometry:c131 : 1
m23*0.1
nodelay
--
0
PMID: 10611754 The mRNAs for Smad6 and Smad7 are rapidly induced by treatment of cells with TGF-beta suggesting that anti-Smads are direct effectors of a ligand-induced signal to suppress a response.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c133 : 1
stoichiometry:c132 : 1
m32*m74*0.1
nodelay
--
0
PMID: 10611754 the MH2 domain of Smad2 interacts with the C-terminal domain (Smad-interaction domain, SID) of FAST-1 directly, while the binding of Smad4 is assumed to be dependent on its association with activated Smad2 and possibly also on its ability to stabilize the DNA complex through its MH1 domain.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c15 : 1
stoichiometry:c26 : 1
stoichiometry:c14 : 1
m2490*m17*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c134 : 1
stoichiometry:c135 : 1
stoichiometry:c136 : 1
m37*m75*0.1
nodelay
--
0
PMID: 10611754, 9732876 Smad3 can interact directly with c-Jun and c-Fos through its MH1 and MH2 domains, respectively leading to the suggestion that AP-1 DNA binding sites can be activated either by direct binding of Smad3 and Smad4 to the DNA element itself or by interaction of the heteromeric Smad3/Smad4 complex and the AP-1 transcription factor complex, in such a manner as to provide additional stability to the complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c138 : 1
stoichiometry:c139 : 1
m37*m221*0.1
nodelay
--
0
PMID: 10611754, 9732876 Smad3 can interact directly with c-Jun and c-Fos through its MH1 and MH2 domains, respectively leading to the suggestion that AP-1 DNA binding sites can be activated either by direct binding of Smad3 and Smad4 to the DNA element itself or by interaction of the heteromeric Smad3/Smad4 complex and the AP-1 transcription factor complex, in such a manner as to provide additional stability to the complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c140 : 1
stoichiometry:c144 : 1
stoichiometry:c155 : 1
stoichiometry:c148 : 1
m27*m78*0.1
nodelay
--
0
PMID: 10611754 These proteins have now been shown to also interact with Smad proteins in the regulation of transcription. PMID: 10611754, 9689110 The essential nature of this interaction is demonstrated by the fact that disruption of the Smad-CBP/p300 interaction by the adenoviral transforming protein E1A, which binds the coactivators, blocks nearly all Smad-stimulated transcriptional responses in cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c141 : 1
stoichiometry:c145 : 1
stoichiometry:c156 : 1
stoichiometry:c149 : 1
m32*m78*0.1
nodelay
--
0
PMID: 10611754, 9679060, 9865696 Depending on the system and the cell type, ligand-activated Smad1, Smad2, and Smad3, as well as Smad4 have all been shown to be capable of binding to CBP/p300. PMID: 10611754, 9689110 The essential nature of this interaction is demonstrated by the fact that disruption of the Smad-CBP/p300 interaction by the adenoviral transforming protein E1A, which binds the coactivators, blocks nearly all Smad-stimulated transcriptional responses in cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c146 : 1
stoichiometry:c157 : 1
stoichiometry:c150 : 1
m37*m78*0.1
nodelay
--
0
PMID: 10611754, 9679060, 9865696 Depending on the system and the cell type, ligand-activated Smad1, Smad2, and Smad3, as well as Smad4 have all been shown to be capable of binding to CBP/p300. PMID: 10611754, 9689110 The essential nature of this interaction is demonstrated by the fact that disruption of the Smad-CBP/p300 interaction by the adenoviral transforming protein E1A, which binds the coactivators, blocks nearly all Smad-stimulated transcriptional responses in cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c143 : 1
stoichiometry:c147 : 1
stoichiometry:c158 : 1
stoichiometry:c151 : 1
m68*m78*0.1
nodelay
--
0
PMID: 10611754, 9679060, 9865696 Depending on the system and the cell type, ligand-activated Smad1, Smad2, and Smad3, as well as Smad4 have all been shown to be capable of binding to CBP/p300. PMID: 10611754, 9689110 The essential nature of this interaction is demonstrated by the fact that disruption of the Smad-CBP/p300 interaction by the adenoviral transforming protein E1A, which binds the coactivators, blocks nearly all Smad-stimulated transcriptional responses in cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c153 : 1
stoichiometry:c154 : 1
m78*m3581*0.1
nodelay
--
0
PMID: 10611754, 9689110 The essential nature of this interaction is demonstrated by the fact that disruption of the Smad-CBP/p300 interaction by the adenoviral transforming protein E1A, which binds the coactivators, blocks nearly all Smad-stimulated transcriptional responses in cells.
p57
p57
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c159 : 1
stoichiometry:c160 : 1
stoichiometry:c161 : 1
m96*m84*0.1
nodelay
--
0
PMID: 10611754 Treatment of cells with EGF or hepatocyte growth factor (HGF) results in phosphorylation of Smad1 on these sites by the Erk subfamily of MAP kinases, and in retention of the linker-region phosphorylated Smad1 in the cytoplasm, blocking the nuclear translocation and transcriptional activating activity of Smad1/Smad4 complexes.
p58
p58
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c165 : 1
stoichiometry:c168 : 1
stoichiometry:c172 : 1
stoichiometry:c170 : 1
m2519*m86*m85*0.1
nodelay
--
0
PMID: 10611754 Treatment of cells with EGF or hepatocyte growth factor (HGF) results in phosphorylation of Smad1 on these sites by the Erk subfamily of MAP kinases, and in retention of the linker-region phosphorylated Smad1 in the cytoplasm, blocking the nuclear translocation and transcriptional activating activity of Smad1/Smad4 complexes.
p59
p59
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c166 : 1
stoichiometry:c167 : 1
stoichiometry:c173 : 1
stoichiometry:c169 : 1
m2519*m86*m89*0.1
nodelay
--
0
PMID: 10611754 Treatment of cells with EGF or hepatocyte growth factor (HGF) results in phosphorylation of Smad1 on these sites by the Erk subfamily of MAP kinases, and in retention of the linker-region phosphorylated Smad1 in the cytoplasm, blocking the nuclear translocation and transcriptional activating activity of Smad1/Smad4 complexes.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m2269*m6*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
p60
p60
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c162 : 1
stoichiometry:c163 : 1
stoichiometry:c164 : 1
m88*m2525*0.1
nodelay
--
0
PMID: 10611754 Treatment of cells with EGF or hepatocyte growth factor (HGF) results in phosphorylation of Smad1 on these sites by the Erk subfamily of MAP kinases, and in retention of the linker-region phosphorylated Smad1 in the cytoplasm, blocking the nuclear translocation and transcriptional activating activity of Smad1/Smad4 complexes.
p61
p61
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c175 : 1
stoichiometry:c177 : 1
stoichiometry:c176 : 1
m2422*m89*0.1
nodelay
--
0
PMID: 10611754 Examples are the activating phosphorylation and nuclear translocation of Smad2 following treatment of cells with HGF [54] or activation of the SAPK/JNK pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c181 : 1
stoichiometry:c179 : 1
m85*0.1
nodelay
--
0
PMID: 10611754, 9712726, 10067896 Smad7 is also an important focal point of disparate signaling pathways as evidenced by its induction by EGF [35] and interferon.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c185 : 1
stoichiometry:c180 : 1
m87*0.1
nodelay
--
0
PMID: 10611754, 9712726, 10067896 Smad7 is also an important focal point of disparate signaling pathways as evidenced by its induction by EGF [35] and interferon.
p64
p64
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c182 : 1
stoichiometry:c184 : 1
stoichiometry:c183 : 1
m1639*m90*0.1
nodelay
--
0
PMID: 10611754, 9712726, 10067896 Smad7 is also an important focal point of disparate signaling pathways as evidenced by its induction by EGF [35] and interferon.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c186 : 1
stoichiometry:c187 : 1
stoichiometry:c188 : 1
m27*m91*0.1
nodelay
--
0
PMID: 10611754, 9707553 Another nuclear protein that strongly activates transcription without binding to DNA, MSG1, has been shown to interact functionally with the SAD domain in the middle linker region of Smad4 and to be required for activation of Smad4-dependent transcription in certain cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c23 : 1
stoichiometry:c20 : 1
m1399*m6*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c21 : 1
stoichiometry:c24 : 1
stoichiometry:c22 : 1
m3831*m6*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c29 : 1
stoichiometry:c27 : 1
m16*m2490*0.1
nodelay
--
0
PMID: 10611754 Betaglycan, formerly called the ¡Ætype III receptor', binds all isoforms of TGF-beta, but may play a selective role in facilitating interaction of TGF-beta2 with TBR-II, since this isoform binds to the type II receptor with significantly lower affinity than that of TGF-beta1 and TGF-beta3.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--